Hepatitis C
Undercounted Populations Raise Estimate of True U.S. Hepatitis C Prevalence
- Details
- Category: HCV Epidemiology & Mortality
- Published on Friday, 23 September 2011 00:00
The number of people living with hepatitis C virus (HCV) infection in the U.S. is probably greater than the usual estimate due to undercounting of high-risk populations in household surveys, including prisoners, homeless people, and injection drug users, researchers reported in the September 2011 issue of Liver International.
Pharmasset Starts Trial of PSI-7977 and PSI-938 Oral Regimens for All HCV Genotypes
- Details
- Category: HCV Treatment
- Published on Friday, 23 September 2011 00:00
Pharmasset last week announced the initiation of a new Phase 2b clinical trial that will test the company's investigational nucleotide HCV polymerase inhibitors, PSI-7977 and PSI-938, in various interferon-sparing oral regimens with or without ribavirin.
Telaprevir plus Standard Therapy Can Produce Hepatitis C Cure in Less Time
- Details
- Category: HCV Treatment
- Published on Thursday, 15 September 2011 00:00
Adding the hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) to pegylated interferon plus ribavirin increases the chances of sustained response and many patients achieved a cure with a shorter course of therapy, researchers reported in the September 15, 2011, New England Journal of Medicine.
ICAAC 2011: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People
- Details
- Category: Fibrosis & Cirrhosis
- Published on Monday, 19 September 2011 00:00
Use of didanosine (ddI, Videx) -- along with higher hepatitis C virus (HCV) RNA level, male sex, and older age -- was a significant risk factor for liver fibrosis in people with HIV/HCV coinfection, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.
Early Data on BMS-790052 HCV NS5A Inhibitor Published
- Details
- Category: HCV Treatment
- Published on Monday, 12 September 2011 00:00
Bristol-Myers Squibb's experimental HCV NS5A inhibitor, BMS-790052, demonstrated potent antiviral activity, was well-tolerated, and pharmacokinetic parameters support once-daily dosing, according to a small 14-day proof-of-concept study described in the August 11, 2011, advance online edition of Hepatology.
ICAAC 2011: BMS-790052 plus Standard Therapy Cures Most Genotype 1 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 19 September 2011 00:00
Up to 83% of treatment-naive people with difficult-to-treat genotype 1 hepatitis C virus (HCV) infection achieved sustained virological response (SVR) with the experimental HCV NS5A inhibitor BMS-790052 plus pegylated interferon and ribavirin, according to data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.
PSI-7977 with Standard Therapy Produces 91% Sustained Response
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 09 September 2011 00:00
The experimental hepatitis C virus (HCV) nucleotide analog polymerase inhibitor PSI-7977, used in combination with pegylated interferon and ribavirin, demonstrated a 12-week sustained virological response rate of 91% for previously untreated genotype 1 chronic hepatitis C patients in the ongoing PROTON trial.
Discovery May Aid Development of Hepatitis C Vaccine
- Details
- Category: HCV Vaccines
- Published on Thursday, 15 September 2011 00:00
Australian researchers have shed new light on the natural history of hepatitis C virus (HCV) by performing a longitudinal genetic analysis of the virus in 4 patients from the first few weeks after infection until resolution (spontaneous clearance or establishment of chronic infection).
HALT-C Finds High Rate of Liver-Related Death and Transplants among Interferon Non-Responders
- Details
- Category: HCV Treatment
- Published on Friday, 09 September 2011 00:00
Chronic hepatitis C patients in the HALT-C study who did not achieve sustained response to standard combination therapy or long-term pegylated interferon maintenance therapy had a high rate of liver transplantation and liver-related death, researchers reported in the August 2011 issue of Hepatology.
More Articles...
- TMC435 for Hepatitis C Phase 3 Studies Fully Enrolled, Company Says
- What Factors Influence Adherence to Treatment for Hepatitis C?
- FDA Approves Pegasys plus Ribavirin for Children with Chronic Hepatitis C
- HCV Polymerase Inhibitor PSI-938 Gets Fast Track Status
- Insulin Resistance Affects Sustained Response to Hepatitis C Treatment
Web Design and Development by